作者: Wouter Michiel Kooloos
DOI:
关键词:
摘要: Results from this thesis have elucidated potential genetic markers, which were associated with treatment outcome to MTX and adalimumab. Furthermore, a model for predicting the efficacy of in patients RA was validated two cohorts indicating that by pharmacogenetic is feasible treated MTX. Importantly, definitive conclusions about role predictive factors DMARDS could not be drawn, since these results further replicated future studies. Large randomized prospective studies should planned demonstrate its legitimate cost-effective value before genetically individualized approach applicable daily clinical practice. The pharmacogenetics prediction adverse events DMARDs presented thesis. Hereby, new knowledge added relatively young research field pharmacogenetics, may hopefully lead better strategy